Platelet to albumin ratio as a potential prognostic marker of nephropathy in diabetic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202510882890343

Enrollment

200

Registered

2025-10-22

Start date

2025-12-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

platelet to albumin ratio in nephropathy in diabetic patients

Platelet to albumin ratio in healthy control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: both male and female age more than 18 years

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes mellitus. 2. Acute infections or signs of active inflammation at the time of sampling. 3. Chronic inflammatory or autoimmune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus). 4. Malignancies (known or recently diagnosed). 5. Chronic liver diseases, including cirrhosis or hepatitis. 6. Nephrotic syndrome or other known non-diabetic kidney diseases. 7. Use of immunosuppressive therapy, corticosteroids, or cytotoxic drugs in the past 3 months. 8. Pregnancy

Design outcomes

Primary

Measure	Time frame
Prevalence of DKD, defined according to KDIGO criteria as either decreased eGFR (< 60 mL/min/1.73 m²) or elevated albuminuria (UACR = 30 m	—

Secondary

Measure	Time frame
Performance of PAR in discriminating the presence of DKD, low eGFR, and albuminuria	—

Countries

Egypt

Contacts

Public ContactNadeen samir Mahmoud

residant doctor at Clinical Pathology department Assiut university

Nadeen.17289782@med.aun.edu.eg+201097819857

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026